论文部分内容阅读
目的研究恩替卡韦对防治合并乙型肝炎病毒(HBV)感染的血液系统肿瘤患者化疗后乙型肝炎复发的意义。方法选择合并HBV感染的血液系统肿瘤患者60例,将其随机分为两组。对照组30例,即常规治疗组,化疗期间仅给予常规保肝降酶,未给予恩替卡韦预防治疗;治疗组30例,即给予恩替卡韦预防治疗组,从化疗前1周每次0.5 mg每日1次口服恩替卡韦至化疗结束后6个月,联合常规保肝降酶。结果化疗结束后,治疗组HBV再激活、丙氨酸氨基转移酶升高、总胆红素升高的比率均较对照组明显低。而两组药物不良反应发生率比较,差异无统计学意义。结论恩替卡韦能预防合并HBV感染的血液系统肿瘤患者化疗后乙肝病毒的再激活,且安全性好。
Objective To investigate the significance of entecavir for the prevention and treatment of hepatitis B recurrence in patients with hematologic malignancies complicated by hepatitis B virus (HBV) infection after chemotherapy. Methods Sixty patients with hematological malignancies complicated with HBV infection were selected and randomly divided into two groups. The control group of 30 patients, that is, the conventional treatment group, chemotherapy only given regular liver enzymes, did not give entecavir prophylaxis; treatment group of 30 patients, that is given entecavir prophylaxis treatment group, from the week before chemotherapy, 0.5 mg per day 1 After oral administration of entecavir 6 months after the end of chemotherapy, combined with regular liver enzymes. Results After chemotherapy, the reactivation of HBV, the increase of alanine aminotransferase and the increase of total bilirubin in the treatment group were significantly lower than those in the control group. The incidence of adverse drug reactions between the two groups, the difference was not statistically significant. Conclusion Entecavir can prevent hepatitis B virus reactivation after chemotherapy in patients with hematological malignancies complicated with HBV infection and is safe.